ABT-263 (Navitoclax)
ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki ~ 0.5 nM, 1 nM and 1 nM in cell-free assays. ABT-263 blocks the Bcl-2/Bcl-xL interactions, thereby promoting apoptosis.
Product Name:
ABT-263 (Navitoclax)
>Also Known As:
4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]-benzamide
>Catalog No.:
F7140
>Size:
5 mg
>CAS:
N/A
>Formula:
C47H55ClF3O6S3
>Molecular Weight:
974.61 Da
>Form:
Lyophilized powder
>Quality Assurance:
>98% by HPLC and NMR
>Source:
Synthetic
>Storage:
Eligible for room temperature shipping. Store at -80°C upon receiving
>PDF Data Sheet:
Download PDF datasheet
>Image(s):
N/A
>Shipping Method:
Room temperature shipping
>References:
Tse C, et al. (2008) Cancer Res. 68(9), 3421-3428. GSK269962A 18481316
